Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published: December 2022

No. of Pages: 60

Price:

Single User License: US $ 2000

Corporate User License: US $ 6000

Report Description
Table of Contents

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drugs In Development, 2022, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Incyte Corp
Ipsen SA
La Jolla Pharmaceutical Company
Pfizer Inc
Regeneron Pharmaceuticals Inc
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
DS-6016 - Drug Profile
Product Description
Mechanism Of Action
garetosmab - Drug Profile
Product Description
Mechanism Of Action
INCB-00928 - Drug Profile
Product Description
Mechanism Of Action
IPN-60130 - Drug Profile
Product Description
Mechanism Of Action
palovarotene - Drug Profile
Product Description
Mechanism Of Action
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
sirolimus - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
Featured News & Press Releases
Oct 25, 2022: Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting
Jun 29, 2022: Ipsen announces U.S. FDA priority review for palovarotene new drug application in patients with fibrodysplasia ossificans progressiva following resubmission
Jan 24, 2022: Health Canada approves Ipsens Sohonos (palovarotene capsules) as the first approved treatment for Fibrodysplasia Ossificans Progressiva
Aug 13, 2021: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses
May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)
Oct 30, 2020: Regeneron provides update on the Garetosmab phase 2 LUMINA-1 trial in fibrodysplasia ossificans progressiva (FOP)
Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results
Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting
Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
Jan 10, 2020: Regeneron reports positive data from rare bone disease trials
Jan 09, 2020: Regeneron announces encouraging garetosmab phase 2 results in patients with ultra-rare debilitating bone disease
Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Incyte Corp, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Ipsen SA, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Write comment about above report:

Published By: Global Markets Direct

Product Code: Global Markets Direct8060

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal) - Drugs in Development, 2021 Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal) - Drugs in Development, 2021 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasi...
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2020 Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progres...
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019 Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progres...
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018 Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progres...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *

We're Here To Help You

Request for Sample of this report